Heartland virus (HRTV; genus *Phlebovirus*, family *Phenuiviridae* **\[previously *Bunyaviridae*\]**) is a suspected tickborne pathogen in the United States ([@R1]). The virus was initially identified in 2009, and 9 cases of HRTV disease have been reported in the literature ([@R2]--[@R5]). Despite common features, the full spectrum of illness is unknown. We describe a fatal case of HRTV infection with hemophagocytic lymphohistiocytosis (HLH).

The Case
========

An elderly man from central Missouri, USA, came to the emergency department of a local hospital in June (year redacted) reporting 6 days of nausea, anorexia, and fatigue, followed by confusion and shortness of breath with cough. He denied fever, chills, or chest pain. He worked outdoors and had numerous tick exposures. His medical history included diabetes mellitus, chronic obstructive pulmonary disease, hypertension, coronary artery disease with ischemic cardiomyopathy, hypothyroidism, and rheumatoid arthritis; he was taking prednisone, methotrexate, and adalimumab.

On initial examination, he was afebrile (36.6°C), oriented only to year, and wheezed bilaterally on expiration. Laboratory results ([Table 1](#T1){ref-type="table"}) showed acute kidney injury, transaminitis, and mixed anion-gap metabolic acidosis and respiratory alkalosis. Initial complete blood count results showed normocytic anemia and thrombocytopenia. Total leukocyte count was within reference range, but lymphocyte count showed absolute lymphopenia. Troponin I was mildly elevated without electrocardiographic changes. Results of chest radiography and noncontrast computed tomography of the head were unremarkable. He was transferred to a tertiary care center for management of possible acute coronary syndrome and exacerbation of chronic obstructive pulmonary disease.

###### Selected laboratory values of immunocompromised patient leading to diagnoses of Heartland virus and hemophagocytic lymphohistiocytosis, Missouri, USA\*

  ------------------------------------- ----------------- --------------------------- ------------------------- ------- -------- ------- -------
  Test type                             Reference range   4 mo before symptom onset   Post--symptom onset day                            
  6                                     8                 11                          18                        20                       
  Leukocyte count, × 10^3^ cells/µL     3.8--9.8          13.7                        5.8                       5.00    1.60     0.2     NR
  Absolute neutrophil count, cells/µL   1,800--6,600      7,400                       5,000                     4,100   1,200    \<100   NR
  Absolute lymphocyte count, cells/µL   1,200--3,300      3,300                       700                       500     400      100     NR
  Hemoglobin, g/dL                      13.8--17.2        12.1                        11.8                      10.5    7.1      7.0     NR
  Hematocrit, %                         40.7--50.3        36.4                        32.5                      30.5    21.2     21.2    NR
  Platelets, × 10^3^/µL                 140--440          202                         76                        42      47       19      NR
  International normalized ratio        0.90--1.20        1.06                        1.0                       1.19    1.15     1.47    NR
  Partial thromboplastin time, s        25.0--37.0        46                          40                        53.1    56.6     39.7    38.3
  Lactate dehydrogenase, units/L        100--250          NR                          422                       641     3040     NR      NR
  Haptoglobin, mg/dL                    27--220           NR                          NR                        208     227      NR      NR
  Ferritin, ng/mL                       22--322           NR                          NR                        6,308   53,666   NR      NR
  Fibrinogen, mg/dL                     170--400          NR                          NR                        NR      215      NR      NR
  Sodium, mmol/L                        135--145          139                         128                       141     141      138     136
  Potassium, mmol/L                     3.3--4.9          4.0                         5.1                       5.9     5.1      5.5     4.8
  Carbon dioxide, mmol/L                22--32            27                          13                        15      16       21      25
  Blood urea nitrogen, mg/dL            8--25             16                          90                        63      94       60      50
  Creatinine, mg/dL                     0.70--1.30        1.31                        3.38                      1.75    4.74     1.95†   1.80†
  Troponin I, ng/mL                     0.00--0.03        2.55                        0.76                      0.27    NR       NR      NR
  Cholesterol, total, mg/dL             0--200            258                         115                       NR      NR       NR      NR
  Triglycerides, mg/dL                  0--150            426                         532                       NR      NR       NR      NR
  Aspartate aminotransferase, units/L   11--47            32                          231                       147     684      NR      146
  Alanine aminotransferase, units/L     7--53             17                          186                       112     118      NR      52
  Alkaline phosphatase, units/L         38--126           85                          60                        65      111      NR      65
  Bilirubin, total, mg/dL               0.3--1.1          0.3                         0.1                       0.2     0.2      NR      0.7
  Bilirubin, direct, mg/dL              0.0--0.3          0.1                         0.1                       NR      0.2      NR      NR
  Amylase, units/L                      28--100           NR                          234                       NR      NR       NR      NR
  Lipase, units/L                       0--99             NR                          578                       NR      NR       NR      NR
  pH                                    7.35--7.45        NR                          7.31                      7.17    7.24     7.42    7.32
  P~a~CO~2~, mm Hg                      35--45            NR                          21                        41      38       36      47
  P~a~O~2~, mm Hg                       80--105           NR                          125                       93      108      159     96
  Temperature, °C                       35.5--38.3        NR                          36.6                      38.9    38.2     37.3    35.4
  F~i~O~2~                              0.21              NR                          0.40                      0.40    NR       0.40    NR
  ------------------------------------- ----------------- --------------------------- ------------------------- ------- -------- ------- -------

\*F~i~O~2~, fraction of inspired oxygen; NR, not reported; P~a~CO~2~, arterial partial pressure of carbon dioxide; P~a~O~2~, arterial partial pressure of oxygen. †On continuous venovenous hemodialysis.

On post--symptom onset day (PSOD) 8, the patient became febrile (38.9°C) and increasingly confused; we intubated him for airway protection. We empirically prescribed vancomycin, meropenem, ampicillin, and acyclovir for meningoencephalitis, as well as doxycycline for possible ehrlichiosis ([Figure 1](#F1){ref-type="fig"}). We administered a platelet transfusion to complete a lumbar puncture safely. Lumbar puncture results revealed a mildly elevated cerebrospinal fluid (CSF) protein of 56 mg/dL and an unremarkable CSF glucose level of 64 mg/dL. Specimen tubes 1 and 4 cell counts were, respectively, 14 and 0 leukocytes/µL and 158 and 14 red blood cells/µL.

![Chronology of selected laboratory findings and therapeutic interventions for immunocompromised patient infected with Heartland virus, Missouri, USA. Gray bars indicate treatments administered. CVVHD, continuous veno-venous hemodialysis; IV, intravenous.](17-1802-F1){#F1}

Initial testing for an infectious etiology of the illness was negative ([Table 2](#T2){ref-type="table"}), including a low positive rickettsia IgG titer, for which repeated testing was negative. Chest radiograph on PSOD 11 showed new multifocal infiltrates; a tracheal aspirate grew *Stenotrophomonas maltophilia* in culture, and we started levofloxacin. On the same day, we documented leukopenia, and a core bone marrow biopsy demonstrated hypocellularity for his age without blasts, dysplasia, or atypia. We were unable to obtain an aspirate sample. We suspected HLH; his ferritin had increased from 6,308 ng/mL on PSOD 8 to 53,666 ng/mL on PSOD 11 (reference 22--322 ng/dL). In addition, he had fever, leukopenia, thrombocytopenia, and hypertriglyceridemia ([Table 1](#T1){ref-type="table"}), meeting at that time 4 of 5 required diagnostic criteria by the HLH-2004 Histiocyte Society guidelines ([@R6]). We initiated presumptive HLH treatment with etoposide and high-dose dexamethasone on PSOD 12. We stopped vancomycin and meropenem on PSOD 18 but restarted on PSOD 20 to treat suspected sepsis after hypothermia and hypotension developed. The same day, we started voriconazole therapy to treat the patient for *Aspergillus terreus* identified from a sputum culture taken on PSOD 9. *A. terreus* had been deemed a contaminant, but we subsequently chose to treat it as a pathogen because of the patient's leukopenia and respiratory failure. On PSOD 20, the Centers for Disease Control and Prevention (Fort Collins, CO, USA) notified the clinical care team that a blood sample obtained on PSOD 14 was positive for HRTV RNA) by reverse transcription PCR (RT-PCR) and positive for HRTV neutralizing antibodies by plaque reduction neutralization test (titer 10). Because of the patient's clinical decline, his family elected to transition to comfort care, and he died on PSOD 22.

###### Infectious disease testing of immunocompromised patient after symptom onset, Missouri, USA\*

  PSOD      Test and sample type                             Result
  --------- ------------------------------------------------ -------------------------------------------------------------------------------------
  6         Aerobic culture, urine                           Nonsignificant growth
  7         *Rickettsia* SFG IgG, serum                      **1:64 (normal \<1:64)**
            *Rickettsia* SFG IgM, serum                      \<1:64 (normal \<1:64)
            HIV 1, 2 antibody, serum                         Negative
            Epstein-Barr viral capsid antibody, IgM, serum   Nonreactive
  8         Aerobic and anaerobic culture, blood × 2         No growth
            *Ehrlichia* and *Anaplasma* PCR, blood           Negative
            Enterovirus RT-PCR, CSF                          Negative
            Cytomegalovirus PCR, CSF                         Negative
            West Nile virus IgG, CSF                         Negative
            West Nile virus IgM, CSF                         Negative
            Cryptococcal antigen, CSF                        Negative
            Fungal culture, CSF                              No growth
            Aerobic culture, CSF                             No growth
            Fungal culture, blood                            No growth
  9         Aerobic culture, tracheal aspirate               ***Aspergillus terreus***
            Aerobic culture, urine                           No growth
            Aerobic and anaerobic culture, blood × 2         No growth
  10        Aerobic and anaerobic culture, blood × 2         No growth
            Acid-fast bacilli culture, blood                 No growth
            Fungal culture, blood                            No growth
            *Ehrlichia* and *Anaplasma* PCR, blood           Negative
            Cytomegalovirus PCR, blood                       Not detected
            *Histoplasma* antigen, urine                     Negative
            *Aspergillus*galactomannan antigen, blood        Negative
            *Rickettsia* SFG IgG, serum                      \<1:64 (normal \<1:64)
            *Rickettsia* SFG IgM, serum                      \<1:64 (normal \<1:64)
  11        Aerobic culture, tracheal aspirate               **≥100,000 colonies/mL *Stenotrophomonas maltophilia*; ≥100,000 colonies/mL yeast**
  14        Heartland virus RT-PCR, blood                    **Positive**
  20        Aerobic and anaerobic culture, blood             ***Candida albicans***
            Fungal culture, blood                            No growth
            Cytomegalovirus PCR, blood                       Not detected
  Autopsy   Heartland virus RT-PCR, blood                    **Positive**
            Heartland virus RT-PCR, lymph node               **Positive**
            Heartland virus RT-PCR, spleen                   **Positive**

\*Positive findings are in boldface type. CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; PSOD, post--symptom onset day; RT-PCR, reverse transcription PCR; SFG, spotted fever group.

Autopsy revealed splenomegaly and erythrophagocytosis with histiocytic hyperplasia in bone marrow, spleen, and lymph nodes, consistent with HLH. In addition, disseminated angioinvasive candidiasis was seen, and *Candida albicans* was isolated from blood cultures previously taken on PSOD 20. Central nervous system (CNS) findings included multiple brain infarcts without evidence of meningitis or encephalitis. Grocott's methenamine silver stains of the occipital lobe were negative for yeast. All autopsy tissues were negative by HRTV immunohistochemistry (IHC) performed as previously described ([@R4]). However, the earlier bone marrow core biopsy had extensive HRTV antigen identified by retrospectively performed IHC ([Figure 2](#F2){ref-type="fig"}). Autopsy specimens of blood, lymph nodes, and spleen were positive for HRTV RNA by RT-PCR.

![Immunohistochemistry of bone marrow from immunocompromised patient infected with Heartland virus (HRTV), Missouri, USA. Testing of biopsied sample from post--symptom onset day 11 shows extensive positive staining for HRTV antigen, including erythrophagocytosis by an HRTV-antigen--positive cell (arrowhead). Scale bar indicates 20μm.](17-1802-F2){#F2}

The CSF (tube 4) and blood samples obtained on PSOD 8 were analyzed retrospectively for HRTV by using real-time PCR assay primers and probes as previously described ([@R3]). HRTV RNA was detected in both specimens, although at substantively higher levels in the blood (cycle threshold 20) than in the CSF (cycle threshold 32).

Conclusions
===========

HRTV was first identified in 2009, when 2 Missouri farmers who had been bitten by ticks were admitted to a hospital for fever, fatigue, and anorexia ([@R3]). Since then, descriptions of [\>]{.ul}7 additional cases, including 2 deaths, have been published ([@R2],[@R4],[@R5]). HRTV is believed to be transmitted by the lone star tick (*Amblyomma americanum*) and may be present in various mammals ([@R7]--[@R9]). This patient's condition was similar to those described in the literature, who had fatigue, anorexia, thrombocytopenia, and transaminitis at hospital admission.

HLH is a syndrome of T-cell and macrophage hyperactivation, leading to elevated cytokines and end-organ dysfunction ([@R10]). Secondary HLH is often precipitated by infection, although malignancy and autoimmune diseases are also common precipitants. The HLH-2004 Histiocyte Society guidelines provide 8 diagnostic criteria for the syndrome, 5 of which must be met to establish the diagnosis ([@R6]). However, these guidelines were written on the basis of pediatric case series, and controversy remains regarding their sensitivity, specificity, and applicability in adults with HLH ([@R11]--[@R13]). We identified 4 HLH criteria at the time of treatment: fever, bicytopenia, hypertriglyceridemia, and hyperferritinemia. Two additional criteria, splenomegaly and hemophagocytosis, were documented at autopsy. Tests were not done for natural killer cell activity or soluble CD25 receptor levels.

We cannot directly prove that HRTV infection led to HLH in this case; however, there is a probable association. First, 4 HLH criteria were met on PSOD 8, before the identification of other infections (e.g., *S. maltophilia* pneumonia and candidemia), although these conditions may have contributed to the HLH clinical course once present. Second, HRTV without *Candida* spp. was detectable in the bone marrow at the time HLH was diagnosed, and erythrophagocytosis by HRTV antigen--positive cells in bone marrow were seen in the retrospective IHC analysis ([Figure 2](#F2){ref-type="fig"}). Finally, 1 prior HRTV case report also detected hemophagocytosis in a lymph node ([@R4]).

This patient's severe disseminated HRTV infection may have been exacerbated by his immunosuppressant medications, co-infections, or underlying conditions and could have been further exacerbated by etoposide and dexamethasone treatment. Multiple underlying conditions were also noted in another reported patient with fatal HRTV disease ([@R4]). We detected HRTV RNA in this patient's CSF by RT-PCR, which may reflect CNS dissemination or may be from contamination with blood during the lumbar puncture. Further investigation is necessary to determine if HRTV can invade the CNS.

Increasing recognition of HRTV disease will support generating further data on clinical characteristics of and risk factors for higher severity. Clinicians should be alert to the possibility of severe HRTV disease, including the potential development of HLH, in persons who are immunosuppressed, have multiple concurrent conditions, or both. Early recognition of HLH, treatment of patients diagnosed with this condition, and referral to tertiary care centers should be considered in these situations.
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